BVF Partners, a San Francisco-based private investment partnership, led a $100m Series B funding round in ShouTi, a developer of drugs focused on novel small molecules for multiple unmet medical needs. Additional investors include Casdin Capital, Cormorant Asset Management, Janus Henderson, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital, TCG X, Terra Magnum, Woodline Partners, Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec. Proceeds will be used to advance the company’s discovery platform, which combines state-of-the-art computational chemistry, world-leading structural biology, and large-scale data integration to design orally available medicines with superior properties that overcome current limitations of biologic and peptide drugs. The financing will also drive the continued development of the company’s clinical-stage pipeline, focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions.